Statements (33)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
gptkb:monoclonal_antibody |
| gptkbp:administeredBy |
intravenous infusion
|
| gptkbp:approvalYear |
2020
|
| gptkbp:approvedBy |
gptkb:United_States
gptkb:FDA |
| gptkbp:ATCCode |
L01XC41
|
| gptkbp:brand |
gptkb:Monjuvi
|
| gptkbp:CASNumber |
1610762-09-8
|
| gptkbp:combines |
gptkb:lenalidomide
|
| gptkbp:developedBy |
gptkb:Incyte
gptkb:MorphoSys |
| gptkbp:drugClass |
gptkb:antineoplastic_agent
|
| gptkbp:indication |
relapsed or refractory diffuse large B-cell lymphoma
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:macromoleculeType |
gptkb:CD19
|
| gptkbp:mechanismOfAction |
binds to CD19 on B cells
|
| gptkbp:pregnancyCategory |
not recommended
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
gptkb:anemia
diarrhea fatigue cough neutropenia respiratory tract infection pyrexia peripheral edema |
| gptkbp:target |
gptkb:CD19
|
| gptkbp:UNII |
6QY1D9Y4F1
|
| gptkbp:usedFor |
treatment of diffuse large B-cell lymphoma
|
| gptkbp:bfsParent |
gptkb:Monjuvi
|
| gptkbp:bfsLayer |
6
|
| http://www.w3.org/2000/01/rdf-schema#label |
tafasitamab
|